 target in people with recurrent cardiovascular
events (within two years), based on a limited number of
RCTs in which relatively few participants with CLTI and
diabetes were included. To reach the aforementioned
very low LDL levels, additional treatment with a PCSK9
inhibitor will be necessary in a proportion of people.
PCSK9 inhibitors are monoclonal antibodies that have
limited side effects but have the drawback of high costs,
parenteral administration, and at present there is very